Lumos Pharma Inc (LUMO)

NASDAQ
7.85
+0.24(+3.15%)
  • Volume:
    9,776
  • Day's Range:
    7.39 - 8.29
  • 52 wk Range:
    6.15 - 12.05

LUMO Overview

Prev. Close
7.61
Day's Range
7.39-8.29
Revenue
230K
Open
8.14
52 wk Range
6.15-12.05
EPS
-3.49
Volume
9,776
Market Cap
63.86M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
14,497
P/E Ratio
-
Beta
1.35
1-Year Change
-26.62%
Shares Outstanding
8,369,228
Next Earnings Date
Aug 18, 2022
What is your sentiment on Lumos Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Lumos Pharma Inc News

  • Lumos Pharma, Inc. Misses Q1 EPS by 3c
    • ByInvesting.com-

    Lumos Pharma, Inc. (NASDAQ:LUMO) reported Q1 EPS of ($0.92), $0.03 worse than the analyst estimate of ($0.89).Lumos Pharma ended the quarter on March 31, 2022 with cash and cash...

  • Oncology players in the red on Celgene deal
    • BySeeking Alpha-

    A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb (NYSE:BMY) announced its $74B bid for Celgene (NASDAQ:CELG), thereby removing a...

Lumos Pharma Inc Analysis

Lumos Pharma Inc Company Profile

Lumos Pharma Inc Company Profile

Employees
31

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuySellNeutralSellStrong Sell
Technical IndicatorsBuyBuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyNeutralBuyStrong SellStrong Sell
  • $NLNK Indoximod + gemcitabine and nab-paclitaxel for Pancreatic cancer. Phase 2 data due anytime now. I bought upside calls $20
    0